© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell for USD25m
Posted 12th March 2015

Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell for USD25m

NULL

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell for USD25m
Image

Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell for USD25m

Orgenesis Inc., a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes, today announced the Company’s plan to increase its global presence and capabilities by acquiring MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics, based in Gosselies, Belgium.  

Orgenesis entered into a share exchange agreement with MaSTherCell SA and Cell Therapy Holding SA (collectively “MaSTherCell”) and each of the shareholders of the MaSTherCell, which provides for the acquisition by the Company of all of the issued and outstanding shares of MaSTherCell in exchange for the issuance of $24,593,000 in value of shares of common stock in the capital of the Company.

“The acquisition of MaSTherCell creates incremental value for both companies in business-critical ways.  First, it allows us to accelerate the transition of our lead product, Autologous Insulin Producing Cells (AIPCs) being developed as a therapeutic for Type 1 Diabetes, from pre-clinical testing into clinical trials.  Second, the acquisition will also allow us to diversify our business model and future product offering,” said Vered Caplan, chairperson and CEO of Orgenesis.  “We are creating a vertically integrated company that will deliver more end-user value and generate a stronger financial position for our overall business.  Both businesses will remain operationally independent, but will become strategically aligned in ways that maximize technical, financial and management synergies.  As a result of the acquisition, Orgenesis benefits from deeper involvement in the manufacturing process and resulting cost of goods efficiencies, while MaSTherCell benefits by expanding its international presence and by gaining access to public markets and financing for further technology-based investment.”

Orgenesis is an innovator in the technology of “cellular trans-differentiation.”  This process involves re-programming one adult cell type to function like an adult cell of a different type.  In the case of AIPCs, the company is transforming a type 1 diabetic patient’s own liver cells into insulin-producing cells. Cellular trans-differentiation is accomplished through a complex biologic process, requiring sophisticated manufacturing technology and capabilities.  MaSTherCell has in place a best-in-class combination of the process development capabilities and fully closed and tightly controlled GMP systems required to deliver commercial-scale manufacturing for Orgenesis.  Prior to the acquisition, the two companies have already been working together under a strategic manufacturing agreement.  With the acquisition in place, MaSTherCell will provide services not only to Orgenesis, but will continue to provide broad Contract Development and Manufacturing Services to other cell-based therapeutic companies around the world.

“Cell therapy developments have gained strategic significance in recent years – particularly in the areas of regenerative medicine, ex-vivo gene therapy and immunotherapy of cancer,” said Hugues Bultot, CEO of MaSTherCell.  “Research and scientific development in these sectors has seen rapid progress and because of our ability to innovate, our industrialization and manufacturing expertise has not only kept pace with, but has actually led in terms of the ability of our technology to meet the needs of rapidly evolving science.  Moving forward with Orgenesis, we will continue to provide for our current clients the same unique services but with a larger geographic reach.  By combing our organizations, we will be able to more quickly capitalize on our desires to expand our cell-based therapeutic contract development and manufacturing services internationally.  And, importantly, having access to public markets will enhance our ability to invest in the continued evolution of our technology and capabilities.”

For more information about either company, please visit www.orgenesis.com and www.masthercell.com

Categories: Finance, M&A


You Might Also Like
Read Full PostRead - Eye Icon
Not Losing Interest
Finance
13/02/2017Not Losing Interest

Cavmont Bank Ltd’s vision is to be a world class bank rated amongst the best in Zambia with a focus on partnering with all their stakeholders. Following their success in winning the 2016 Banker of the Year Zambia

Read Full PostRead - Eye Icon
Running a Professional Options Trading Business from Home
Innovation
21/02/2023Running a Professional Options Trading Business from Home

When you run a professional options trading business, you gain the right to buy or sell assets at a set price prior to a specific date. These days, investors can begin options trading from home. Do it right, and you could end up with healthy profits.

Read Full PostRead - Eye Icon
Boxer Capital, LLC
Finance
26/02/2019Boxer Capital, LLC

Boxer Capital, LLC invents and invests in biotechnology companies that aim to drastically improve medicine. To celebrate the firm’s success in this year’s Hedge Fund Awards we profile it to find out more and explore the secrets behind its success.

Read Full PostRead - Eye Icon
Cruz Marcelo & Tenefrancia
Finance
31/08/2016Cruz Marcelo & Tenefrancia

Cruz Marcelo & Tenefrancia is a full-service firm with proven expertise in different practice areas such as corporate and commercial law, intellectual property, litigation and dispute resolution, to name just a few.

Read Full PostRead - Eye Icon
The Smart Choice
Innovation
13/02/2017The Smart Choice

Remfry & Son is a well-established law firm which continues law practice first established in 1827 by its founder Mr. Henry Oliver Remfry of England U.K. and carried on under the name of Remfry & Son by Mr. Chughtai Mirza Jamiluddin, Advocate. Professional pra

Read Full PostRead - Eye Icon
Trowers & Hamlin Advise on Cygnet Healthcare Acquisition of Alpha Hospitals
Legal
27/08/2015Trowers & Hamlin Advise on Cygnet Healthcare Acquisition of Alpha Hospitals

Trowers & Hamlin Advise on Cygnet Healthcare Acquisition of Alpha Hospitals

Read Full PostRead - Eye Icon
August Winners’ Directory
Strategy
31/08/2016August Winners’ Directory

August Winners’ Directory.

Read Full PostRead - Eye Icon
Global Digital Health Solutions Provider Strengthens Home Care and Telecare Delivery in Germany with Acquisition
M&A
04/03/2022Global Digital Health Solutions Provider Strengthens Home Care and Telecare Delivery in Germany with Acquisition

UK based, leading global provider of software solutions, services and technology for the telecare and telehealth markets, Tunstall Healthcare, has expanded its German presence and service offering with the acquisition of BeWo Unternehmensgruppe (BeWo).

Read Full PostRead - Eye Icon
Best AI & Data Advisory Firm – Nordics
Innovation
17/02/2023Best AI & Data Advisory Firm – Nordics

The AI Framework is on a mission towards accomplishing an intelligent future, with its experts dedicated to implementing AI-driven transformations for client organisations. As the company is recognised within the Artificial Intelligence Awards 2022, we got in



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow